Use of gram negative species to treat atopic dermatitis

Abstract

Pharmaceutical compositions are disclosed that includes a therapeutically effective amount of a purified viable gram negative bacteria and a pharmaceutically acceptable carrier. The pharmaceutical compositions are formulated for topical administration. Methods of treating atopic dermatitis using these pharmaceutical compositions are also disclosed.

1 . A pharmaceutical composition, comprising
 at least one species of gram negative bacteria isolated from skin of a subject that does not have atopic dermatitis, wherein the at least one species of gram negative bacteria is present in an amount sufficient for treatment of atopic dermatitis in a subject in need thereof; and   a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is formulated in a topical dosage form selected from a cream, gel, foam, ointment and a lotion.   
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the at least one species of gram negative bacteria comprises a species of  Pseudomonas.    
     
     
         3 . The pharmaceutical composition of  claim 2 , wherein the species of  Pseudomonas  is  Pseudomonas aeruginosa, Pseudomonas luteola,  or  Pseudomonas orbyhabitans.    
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the at least one species of gram negative bacteria comprises a species of  Pantoea.    
     
     
         5 . The pharmaceutical composition of  claim 4 , wherein the species of  Pantoea  is  Pantoea septica.    
     
     
         6 . The pharmaceutical composition of  claim 1 , wherein the at least one species of gram negative bacteria comprises a species of  Moraxella.    
     
     
         7 . The pharmaceutical composition of  claim 6 , wherein the species of  Moraxella  is  Moraxella osloensis.    
     
     
         8 . The pharmaceutical composition of  claim 1 , wherein the at least one species of gram negative bacteria comprises  Acinetobacter radioresistens, Moraxella osloensis, Pantoea septica, Pseudomonas luteola, Pseudomonas aeruginosa, Pseudomonas oryzibhabitns,  or  Methylobacterium  spp. 
     
     
         9 . The pharmaceutical composition of  claim 1 , wherein the at least one species of gram negative bacteria is present in an amount of 10 4  to 10 12  colony forming units 
     
     
         10 . The pharmaceutical composition of  claim 1 , wherein the at least one species of gram negative bacteria is viable. 
     
     
         11 . The pharmaceutical composition of  claim 1 , wherein the at least one species of gram negative bacteria is purified. 
     
     
         12 . The pharmaceutical composition of  claim 1 , wherein the at least one species of gram negative bacteria comprises up to three strains of a single species of gram negative bacteria. 
     
     
         13 . The pharmaceutical composition of  claim 1 , wherein the at least one species of gram negative bacteria comprises up to five strains of a single species of gram negative bacteria. 
     
     
         14 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutically acceptable carrier comprises sucrose. 
     
     
         15 - 20 . (canceled) 
     
     
         21 . The pharmaceutical composition of  claim 12 , wherein the single species of gram negative bacteria is  Acinetobacter radioresistens, Moraxella osloensis, Pantoea septica, Pseudomonas luteola, Pseudomonas aeruginosa,  or  Pseudomonas oryzibhabitns.    
     
     
         22 . The pharmaceutical composition of  claim 13 , wherein the single species of gram negative bacteria is  Acinetobacter radioresistens, Moraxella osloensis, Pantoea septica, Pseudomonas luteola, Pseudomonas aeruginosa,  or  Pseudomonas oryzibhabitns.